By Devika Patel
Knoxville, Tenn., March 5 - Optimer Pharmaceuticals, Inc. arranged a $5 million direct offering of units and a $27.95 million direct offering of stock on March 4, according to two prospectus supplements filed with the Securities and Exchange Commission.
The company will sell 457,666 units at $10.925 each and 2,794,700 shares at $10.00 apiece.
The units consist of one common share and one warrant for 0.20 of a share. Each whole warrant is exercisable at $10.93 for five years.
Settlement of both deals is expected March 9.
Proceeds will be used primarily to fund clinical and pre-clinical development of Optimer's product candidates, preparation and submission of regulatory filings related to the company's product candidates, pre-launch commercialization and marketing activities, a milestone payment of $5 million to Par Pharmaceutical, Inc. and for general corporate purposes.
San Diego-based Optimer Pharmaceuticals is a biopharmaceutical company specializing on the discovering, developing and commercializing of innovative treatments.
Issuer: | Optimer Pharmaceuticals, Inc.
|
Issue: | Common stock, units of one common share and one warrant for 0.20 of a share
|
Amount: | $32,947,001
|
Pricing date: | March 4
|
Settlement date: | March 9
|
Stock symbol: | Nasdaq: OPTR
|
Stock price: | $10.93 at close March 4
|
Market capitalization: | $321 million
|
|
Shares
|
Amount: | $27,947,000
|
Shares: | 2,794,700
|
Price: | $10.00
|
Warrants: | No
|
|
Units
|
Amount: | $5,000,001
|
Units: | 457,666
|
Price: | $10.925
|
Warrants: | One warrant for 0.20 of a share per unit
|
Warrant expiration: | Five years
|
Warrant strike price: | $10.93
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.